Required efficacy for novel therapies in BCG‐unresponsive non‐muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?

BACKGROUND: Single‐arm trials are currently an accepted study design to investigate the efficacy of novel therapies (NT) in non‐muscle invasive bladder cancer (NMIBC) unresponsive to intravesical Bacillus Calmette‐Guérin (BCG) immunotherapy as randomized controlled trials are either unfeasible (comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Wettstein, Marian S., Naimark, David, Hermanns, Thomas, Herrera‐Caceres, Jaime O., Ahmad, Ardalan, Jewett, Michael A.S., Kulkarni, Girish S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221312/
https://www.ncbi.nlm.nih.gov/pubmed/32163677
http://dx.doi.org/10.1002/cam4.2980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221312/
https://www.ncbi.nlm.nih.gov/pubmed/32163677
http://dx.doi.org/10.1002/cam4.2980

Ejemplares similares